South Carolina Plaintiff Latest to Make Actos Lawsuit News
Yet another Actos bladder cancer lawsuit has been filed in the growing mass tort litigation centered in the Circuit Court of Cook County, Illinois. Ronald C. Brewer, Jr., a resident of South Carolina, filed his multi-count Actos cancer lawsuit on April 16, 2012. According to Brewer’s Actos lawyer, he developed bladder cancer in 2011 after using Takeda Pharmaceutical’s Type II diabetes medication.
Brewer alleges that Takeda failed to warn him of the high risk of developing bladder cancer faced by patients who use the medication for the long-term management of diabetes. Had he known of the danger, he asserts, he would not have taken the drug.
Through his Actos lawyer, Brewer is seeking compensation for his pain, suffering, disability, medical expenses, and other economic losses occasioned by his injuries.
Actos lawsuit news signals continued struggles for Takeda
Takeda Pharmaceuticals, whose North American operations are based in Illinois, has faced Actos bladder cancer lawsuit filings for some time. Due to the volume of actions, the Illinois Supreme Court established a mass tort to manage the claims as a consolidated process. The Illinois mass tort is under the supervision of Circuit Court Judge Deborah Dooling.
At the same time, Takeda is fighting federal Actos bladder cancer lawsuit actions in the multidistrict litigation that has been established in the U.S. District Court for the Western District of Louisiana. Cases filed by an Actos lawyer on behalf of plaintiffs in the federal MDL are under the supervision of Judge Rebecca F. Doherty.
Actos lawyer activity increases scrutiny for drug in U.S. and abroad
Clinical studies have demonstrated that the use of Actos for more than 12 months places diabetes patients at a high risk of developing bladder cancer. This evidence prompted several European countries to suspend the sales of Actos, and the drug was recalled in France in 2011. These actions have been cited in numerous Actos bladder cancer lawsuit actions as evidence that Takeda was aware of the drug’s risks.
Though the medication remains available on the U.S. market, patient complaints and Actos lawyer advocacy has caught the attention of the FDA. In 2011, the agency issued a warning that “use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.”